Northern Trust
PHAT icon

Northern Trust’s Phathom Pharmaceuticals PHAT Stock Holding History

Northern Trust’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.97M Buy
458,301
+43,345
+10% +$495K ﹤0.01% 2627
2026
Q1 		$4.61M Buy
414,956
+58,490
+16% +$739K ﹤0.01% 2492
2025
Q4 		$5.91M Sell
356,466
-1,112
-0.3% -$15.9K ﹤0.01% 2373
2025
Q3 		$4.21M Sell
357,578
-1,746
-0.5% -$18K ﹤0.01% 2604
2025
Q2 		$3.45M Sell
359,324
-27,299
-7% -$151K ﹤0.01% 2688
2025
Q1 		$2.42M Sell
386,623
-11,341
-3% -$68.9K ﹤0.01% 2817
2024
Q4 		$3.23M Buy
397,964
+77,189
+24% +$956K ﹤0.01% 2766
2024
Q3 		$5.8M Buy
320,775
+44,115
+16% +$617K ﹤0.01% 2394
2024
Q2 		$2.85M Sell
276,660
-6,540
-2% -$67.4K ﹤0.01% 2712
2024
Q1 		$3.01M Sell
283,200
-6,619
-2% -$56.2K ﹤0.01% 2760
2023
Q4 		$2.65M Buy
289,819
+21,043
+8% +$181K ﹤0.01% 2843
2023
Q3 		$2.79M Buy
268,776
+51,590
+24% +$708K ﹤0.01% 2759
2023
Q2 		$3.11M Buy
217,186
+4,285
+2% +$49.4K ﹤0.01% 2761
2023
Q1 		$1.52M Buy
212,901
+1,852
+0.9% +$16.3K ﹤0.01% 3060
2022
Q4 		$2.37M Buy
211,049
+19,340
+10% +$199K ﹤0.01% 2911
2022
Q3 		$2.12M Buy
191,709
+1,821
+1% +$17.4K ﹤0.01% 2985
2022
Q2 		$1.6M Buy
189,888
+11,078
+6% +$114K ﹤0.01% 3174
2022
Q1 		$2.43M Sell
178,810
-9,095
-5% -$147K ﹤0.01% 3004
2021
Q4 		$3.7M Buy
187,905
+1,829
+1% +$43K ﹤0.01% 2888
2021
Q3 		$5.97M Sell
186,076
-8,800
-5% -$292K ﹤0.01% 2619
2021
Q2 		$6.6M Buy
194,876
+63,020
+48% +$2.26M ﹤0.01% 2659
2021
Q1 		$4.95M Buy
131,856
+535
+0.4% +$22.4K ﹤0.01% 2749
2020
Q4 		$4.36M Sell
131,321
-1,127
-0.9% -$45.7K ﹤0.01% 2759
2020
Q3 		$4.86M Sell
132,448
-11,005
-8% -$381K ﹤0.01% 2549
2020
Q2 		$4.72M Buy
143,453
+12,195
+9% +$469K ﹤0.01% 2562
2020
Q1 		$3.39M Buy
131,258
+16,832
+15% +$563K ﹤0.01% 2530
2019
Q4 		$3.56M Buy
+114,426
New +$2.88M ﹤0.01% 2789

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Northern Trust's PHAT Position: Q2 2026 in Review

Northern Trust increased its Phathom Pharmaceuticals (PHAT) stake by 10% in Q2 2026, buying an estimated $495K and bringing the position to 458,301 shares worth $4.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2627.

Northern Trust first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $6.6M in Q2 2021. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Northern Trust held 458,301 shares of Phathom Pharmaceuticals worth $4.97M as of Q2 2026.
  • Northern Trust bought 43,345 Phathom Pharmaceuticals shares in Q2 2026, an estimated $495K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2627 holding.
  • Northern Trust first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Northern Trust's Phathom Pharmaceuticals position peaked at $6.6M in Q2 2021.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.